Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Common ELF1 deletion in prostate cancer bolsters oncogenic ETS function, inhibits senescence and promotes docetaxel resistance.

Budka JA, Ferris MW, Capone MJ, Hollenhorst PC.

Genes Cancer. 2018 May;9(5-6):198-214. doi: 10.18632/genesandcancer.182.

2.

Electrostatic repulsion causes anticooperative DNA binding between tumor suppressor ETS transcription factors and JUN-FOS at composite DNA sites.

Madison BJ, Clark KA, Bhachech N, Hollenhorst PC, Graves BJ, Currie SL.

J Biol Chem. 2018 Nov 30;293(48):18624-18635. doi: 10.1074/jbc.RA118.003352. Epub 2018 Oct 12.

PMID:
30315111
3.

Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.

Damayanti NP, Budka JA, Khella HWZ, Ferris MW, Ku SY, Kauffman E, Wood AC, Ahmed K, Chintala VN, Adelaiye-Ogala R, Elbanna M, Orillion A, Chintala S, Kao C, Linehan WM, Yousef GM, Hollenhorst PC, Pili R.

Clin Cancer Res. 2018 Dec 1;24(23):5977-5989. doi: 10.1158/1078-0432.CCR-18-0269. Epub 2018 Jul 30.

PMID:
30061365
4.

ETS1 induction by the microenvironment promotes ovarian cancer metastasis through focal adhesion kinase.

Tomar S, Plotnik JP, Haley J, Scantland J, Dasari S, Sheikh Z, Emerson R, Lenz D, Hollenhorst PC, Mitra AK.

Cancer Lett. 2018 Feb 1;414:190-204. doi: 10.1016/j.canlet.2017.11.012. Epub 2017 Nov 22.

5.

Phosphorylation of the oncogenic transcription factor ERG in prostate cells dissociates polycomb repressive complex 2, allowing target gene activation.

Kedage V, Strittmatter BG, Dausinas PB, Hollenhorst PC.

J Biol Chem. 2017 Oct 20;292(42):17225-17235. doi: 10.1074/jbc.M117.796458. Epub 2017 Sep 8.

6.

Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma.

Potu H, Peterson LF, Kandarpa M, Pal A, Sun H, Durham A, Harms PW, Hollenhorst PC, Eskiocak U, Talpaz M, Donato NJ.

Nat Commun. 2017 Feb 15;8:14449. doi: 10.1038/ncomms14449.

7.

Interaction with ZMYND11 mediates opposing roles of Ras-responsive transcription factors ETS1 and ETS2.

Plotnik JP, Hollenhorst PC.

Nucleic Acids Res. 2017 May 5;45(8):4452-4462. doi: 10.1093/nar/gkx039.

8.

Genome-Wide Analysis of RAS/ERK Signaling Targets.

Plotnik JP, Hollenhorst PC.

Methods Mol Biol. 2017;1487:277-288.

PMID:
27924575
9.

An Interaction with Ewing's Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in Prostate Cancer.

Kedage V, Selvaraj N, Nicholas TR, Budka JA, Plotnik JP, Jerde TJ, Hollenhorst PC.

Cell Rep. 2016 Oct 25;17(5):1289-1301. doi: 10.1016/j.celrep.2016.10.001.

10.
11.

Extracellular signal-regulated kinase signaling regulates the opposing roles of JUN family transcription factors at ETS/AP-1 sites and in cell migration.

Selvaraj N, Budka JA, Ferris MW, Plotnik JP, Hollenhorst PC.

Mol Cell Biol. 2015 Jan;35(1):88-100. doi: 10.1128/MCB.00982-14. Epub 2014 Oct 20.

12.

ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells.

Plotnik JP, Budka JA, Ferris MW, Hollenhorst PC.

Nucleic Acids Res. 2014 Oct 29;42(19):11928-40. doi: 10.1093/nar/gku929. Epub 2014 Oct 7.

13.

Prostate cancer ETS rearrangements switch a cell migration gene expression program from RAS/ERK to PI3K/AKT regulation.

Selvaraj N, Budka JA, Ferris MW, Jerde TJ, Hollenhorst PC.

Mol Cancer. 2014 Mar 19;13:61. doi: 10.1186/1476-4598-13-61.

14.

At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone.

Foley J, Nickerson N, Riese DJ 2nd, Hollenhorst PC, Lorch G, Foley AM.

Odontology. 2012 Jul;100(2):109-29. doi: 10.1007/s10266-012-0070-5. Epub 2012 Jun 10. Review.

15.

RAS/ERK pathway transcriptional regulation through ETS/AP-1 binding sites.

Hollenhorst PC.

Small GTPases. 2012 Jul-Sep;3(3):154-8. doi: 10.4161/sgtp.19630. Epub 2012 Jun 1.

16.

Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells.

Hollenhorst PC, Ferris MW, Hull MA, Chae H, Kim S, Graves BJ.

Genes Dev. 2011 Oct 15;25(20):2147-57. doi: 10.1101/gad.17546311.

17.

Genomic and biochemical insights into the specificity of ETS transcription factors.

Hollenhorst PC, McIntosh LP, Graves BJ.

Annu Rev Biochem. 2011;80:437-71. doi: 10.1146/annurev.biochem.79.081507.103945. Review.

18.
19.

Human RNA polymerase III transcriptomes and relationships to Pol II promoter chromatin and enhancer-binding factors.

Oler AJ, Alla RK, Roberts DN, Wong A, Hollenhorst PC, Chandler KJ, Cassiday PA, Nelson CA, Hagedorn CH, Graves BJ, Cairns BR.

Nat Struct Mol Biol. 2010 May;17(5):620-8. doi: 10.1038/nsmb.1801. Epub 2010 Apr 25.

20.

DNA specificity determinants associate with distinct transcription factor functions.

Hollenhorst PC, Chandler KJ, Poulsen RL, Johnson WE, Speck NA, Graves BJ.

PLoS Genet. 2009 Dec;5(12):e1000778. doi: 10.1371/journal.pgen.1000778. Epub 2009 Dec 18.

21.

The GNUMAP algorithm: unbiased probabilistic mapping of oligonucleotides from next-generation sequencing.

Clement NL, Snell Q, Clement MJ, Hollenhorst PC, Purwar J, Graves BJ, Cairns BR, Johnson WE.

Bioinformatics. 2010 Jan 1;26(1):38-45. doi: 10.1093/bioinformatics/btp614. Epub 2009 Oct 27.

22.

Microsatellites as EWS/FLI response elements in Ewing's sarcoma.

Gangwal K, Sankar S, Hollenhorst PC, Kinsey M, Haroldsen SC, Shah AA, Boucher KM, Watkins WS, Jorde LB, Graves BJ, Lessnick SL.

Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10149-54. doi: 10.1073/pnas.0801073105. Epub 2008 Jul 14.

23.

Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family.

Hollenhorst PC, Shah AA, Hopkins C, Graves BJ.

Genes Dev. 2007 Aug 1;21(15):1882-94. Epub 2007 Jul 24.

24.

Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors.

Hollenhorst PC, Jones DA, Graves BJ.

Nucleic Acids Res. 2004 Oct 21;32(18):5693-702. Print 2004.

Supplemental Content

Loading ...
Support Center